Stay updated on Ipilimumab Nivolumab Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab Combo in Melanoma Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab Combo in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe page now includes Melanoma and related topics, such as MedlinePlus Genetics.SummaryDifference0.2%

- Check9 days agoChange DetectedMelanoma and the related topic MedlinePlus Genetics were removed from the page.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded Melanoma label and related topics (MedlinePlus Genetics). Site revision updated to v3.5.0, replacing v3.4.3.SummaryDifference0.2%

- Check30 days agoChange DetectedRevision: v3.4.3 added and v3.4.2 removed.SummaryDifference0.1%

- Check37 days agoChange DetectedThe study page no longer lists Melanoma as the primary condition, and the 'MedlinePlus Genetics' related topics section has been removed.SummaryDifference0.2%

- Check59 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding operating-status banner. Core study content, including eligibility criteria, interventions, and outcomes, remains unchanged.SummaryDifference0.4%

Stay in the know with updates to Ipilimumab Nivolumab Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab Combo in Melanoma Clinical Trial page.